JP2007519631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519631A5 JP2007519631A5 JP2006547015A JP2006547015A JP2007519631A5 JP 2007519631 A5 JP2007519631 A5 JP 2007519631A5 JP 2006547015 A JP2006547015 A JP 2006547015A JP 2006547015 A JP2006547015 A JP 2006547015A JP 2007519631 A5 JP2007519631 A5 JP 2007519631A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- phenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 47
- 239000001257 hydrogen Substances 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 31
- -1 cyano, amino Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000003282 alkyl amino group Chemical group 0.000 claims 13
- 125000004663 dialkyl amino group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000005059 halophenyl group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- ZCOVXTNHLNZJRU-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=C1 ZCOVXTNHLNZJRU-UHFFFAOYSA-N 0.000 claims 4
- LJQBYRXOLRROPZ-UHFFFAOYSA-N 4-(3-cyclopentylindol-1-yl)sulfonyl-n-[(4-fluorophenyl)methyl]benzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCCC3)=C2)C=C1 LJQBYRXOLRROPZ-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- NVSLHEAGBJMNIK-UHFFFAOYSA-N [4-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-(4-phenylpiperazin-1-yl)methanone Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3CC2)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC=C1 NVSLHEAGBJMNIK-UHFFFAOYSA-N 0.000 claims 2
- KMOHVMFBXIPKHP-UHFFFAOYSA-N [4-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3CC2)C=CC=1C(=O)N1CCOCC1 KMOHVMFBXIPKHP-UHFFFAOYSA-N 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003337 fertilizer Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims 1
- UBJIIXJLBJGGDG-UHFFFAOYSA-N 4-(3-cyclopentylindol-1-yl)sulfonyl-n-(oxan-4-yl)benzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCCC3)=C2)C=CC=1C(=O)NC1CCOCC1 UBJIIXJLBJGGDG-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MEFNEHAZMVPNPF-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=CC=1C(=O)NCC1CC1 MEFNEHAZMVPNPF-UHFFFAOYSA-N 0.000 claims 1
- DMIBVXYCEJOIJQ-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=CC=1C(=O)NCC1CCOCC1 DMIBVXYCEJOIJQ-UHFFFAOYSA-N 0.000 claims 1
- TVFAHEGTZFKRKE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-[3-(oxan-4-yl)indol-1-yl]sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCOCC3)=C2)C=C1 TVFAHEGTZFKRKE-UHFFFAOYSA-N 0.000 claims 1
- UMPBSICZALFVFE-UHFFFAOYSA-N n-[(5-fluoropyridin-3-yl)methyl]-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound FC1=CN=CC(CNC(=O)C=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)=C1 UMPBSICZALFVFE-UHFFFAOYSA-N 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CCC(CC)N1CCN(*)CC1 Chemical compound CCC(CC)N1CCN(*)CC1 0.000 description 7
- JVJMCIOGNAMETD-RNPBPNGMSA-N C/C=N\C=C/C=C Chemical compound C/C=N\C=C/C=C JVJMCIOGNAMETD-RNPBPNGMSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1cnncc1 Chemical compound c1cnncc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- JYWDEIHOHORTHJ-ARJAWSKDSA-N C/C=C\[I]=N/N=C Chemical compound C/C=C\[I]=N/N=C JYWDEIHOHORTHJ-ARJAWSKDSA-N 0.000 description 1
- OWJIDQBBMFPTEP-UHFFFAOYSA-N C1=CC=CC2N=[I]C=CC12 Chemical compound C1=CC=CC2N=[I]C=CC12 OWJIDQBBMFPTEP-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- PYCFYVIRXJRSDS-UHFFFAOYSA-N CCC(CC)N1CCCCC1 Chemical compound CCC(CC)N1CCCCC1 PYCFYVIRXJRSDS-UHFFFAOYSA-N 0.000 description 1
- RCDHHTINEDQWDI-UHFFFAOYSA-N CCC(CC)N1CCSCC1 Chemical compound CCC(CC)N1CCSCC1 RCDHHTINEDQWDI-UHFFFAOYSA-N 0.000 description 1
- WEBOPFRMJGAKPV-UHFFFAOYSA-N CCCC(CC)N1CCOCC1 Chemical compound CCCC(CC)N1CCOCC1 WEBOPFRMJGAKPV-UHFFFAOYSA-N 0.000 description 1
- JZDSOQSUCWVBMV-UHFFFAOYSA-N CCN(C(c1c2cccc1)=O)C2=O Chemical compound CCN(C(c1c2cccc1)=O)C2=O JZDSOQSUCWVBMV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53224703P | 2003-12-23 | 2003-12-23 | |
| PCT/US2004/039763 WO2005066126A1 (en) | 2003-12-23 | 2004-12-13 | Cb1 modulator compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519631A JP2007519631A (ja) | 2007-07-19 |
| JP2007519631A5 true JP2007519631A5 (enExample) | 2008-02-07 |
Family
ID=34748790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547015A Pending JP2007519631A (ja) | 2003-12-23 | 2004-12-13 | Ｃｂ１モジュレーター化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7276516B2 (enExample) |
| EP (1) | EP1699761B1 (enExample) |
| JP (1) | JP2007519631A (enExample) |
| AR (1) | AR047160A1 (enExample) |
| AT (1) | ATE502009T1 (enExample) |
| AU (1) | AU2004312311A1 (enExample) |
| BR (1) | BRPI0418079A (enExample) |
| CA (1) | CA2549396A1 (enExample) |
| DE (1) | DE602004031875D1 (enExample) |
| ES (1) | ES2360112T3 (enExample) |
| IL (1) | IL176069A0 (enExample) |
| NO (1) | NO20063381L (enExample) |
| PE (1) | PE20050598A1 (enExample) |
| SV (1) | SV2005001984A (enExample) |
| TW (1) | TW200522944A (enExample) |
| WO (1) | WO2005066126A1 (enExample) |
| ZA (1) | ZA200605159B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ATE359075T1 (de) | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| US7544676B2 (en) * | 2005-11-10 | 2009-06-09 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| FR2893615B1 (fr) * | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
| WO2007098418A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| WO2007138611A1 (en) * | 2006-05-30 | 2007-12-06 | Suven Life Sciences Limited | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands |
| US9079854B2 (en) | 2007-07-13 | 2015-07-14 | The Cleveland Clinic Foundation | Hydrazone modulators of cannabinoid receptors |
| US8309595B2 (en) * | 2007-07-13 | 2012-11-13 | Board Of Regents, The University Of Texas System | Hydrazone modulators of cannabinoid receptors |
| US7759335B2 (en) * | 2008-01-31 | 2010-07-20 | Jenrm Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| US20100056491A1 (en) * | 2008-08-29 | 2010-03-04 | Memory Pharmaceuticals Corporation | 4'-amino cyclic compounds having 5-ht6 receptor affinity |
| US8318725B2 (en) * | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2944788C (en) * | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| CN102844313B (zh) | 2010-01-28 | 2016-10-05 | 哈佛大学校长及研究员协会 | 提高蛋白酶体活性的组合物和方法 |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| MY159058A (en) | 2011-02-25 | 2016-12-15 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent |
| WO2012143522A1 (en) | 2011-04-20 | 2012-10-26 | Glaxo Group Limited | Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds |
| US9556166B2 (en) * | 2011-05-12 | 2017-01-31 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| CN104169287A (zh) * | 2012-01-16 | 2014-11-26 | 拜耳知识产权有限责任公司 | 作为促性腺激素释放激素受体拮抗剂的螺二氢吲哚衍生物 |
| EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| TW201410243A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| RU2557971C2 (ru) * | 2013-07-31 | 2015-07-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ воздействия на функциональную активность каннабиноидного рецептора |
| RU2582393C2 (ru) * | 2013-07-31 | 2016-04-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения ожирения и сопутствующих метаболических расстройств |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US10045979B2 (en) * | 2014-05-19 | 2018-08-14 | Merial Inc. | Anthelmintic compounds |
| RU2016149804A (ru) * | 2014-05-23 | 2018-06-26 | Ф. Хоффманн-Ля Рош Аг | Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой |
| CA3021095A1 (en) | 2016-04-15 | 2017-10-19 | Sre Wellness Inc. | Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions |
| EP3442521A4 (en) | 2016-04-15 | 2020-01-01 | SRE Wellness, Inc. | SWEETENERS AND ELIXIRS INFused WITH CANNABIS |
| US20220087972A9 (en) | 2016-04-15 | 2022-03-24 | Sre Wellness, Inc. | Cannabinoid Compositions |
| CN106349196B (zh) * | 2016-08-26 | 2019-01-04 | 江苏克胜作物科技有限公司 | 一种呋虫胺的合成方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018210658A1 (en) * | 2017-05-15 | 2018-11-22 | Basf Se | Heteroaryl compounds as agrochemical fungicides |
| AU2019391109A1 (en) * | 2018-12-07 | 2021-06-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
| TW202220958A (zh) * | 2020-08-07 | 2022-06-01 | 美商卡司馬療法公司 | Ｔｒｐｍｌ調節劑 |
| CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
| US20250333406A1 (en) * | 2022-05-31 | 2025-10-30 | Lysoway Therapeutics, Inc. | Sulfonyl cyclic derivatives, and compositions and methods thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| ES2213892T3 (es) | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
| PT966436E (pt) | 1997-02-21 | 2003-03-31 | Bayer Ag | Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| WO1999002499A1 (en) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| WO2000030683A1 (en) * | 1998-11-19 | 2000-06-02 | Shionogi & C0., Ltd. | Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| WO2002047679A2 (en) * | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| US6974810B2 (en) | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| ATE504568T1 (de) * | 2003-08-07 | 2011-04-15 | Nat Health Research Institutes | Indol-verbindungen als inhibitoren der tubulin- polymerisation zur behandlung von angiogenesisbezogenen erkrankungen |
-
2004
- 2004-11-23 TW TW093136000A patent/TW200522944A/zh unknown
- 2004-12-10 PE PE2004001249A patent/PE20050598A1/es not_active Application Discontinuation
- 2004-12-13 CA CA002549396A patent/CA2549396A1/en not_active Abandoned
- 2004-12-13 DE DE602004031875T patent/DE602004031875D1/de not_active Expired - Lifetime
- 2004-12-13 BR BRPI0418079-8A patent/BRPI0418079A/pt not_active IP Right Cessation
- 2004-12-13 US US10/596,495 patent/US7276516B2/en not_active Expired - Fee Related
- 2004-12-13 WO PCT/US2004/039763 patent/WO2005066126A1/en not_active Ceased
- 2004-12-13 EP EP04812310A patent/EP1699761B1/en not_active Expired - Lifetime
- 2004-12-13 ES ES04812310T patent/ES2360112T3/es not_active Expired - Lifetime
- 2004-12-13 JP JP2006547015A patent/JP2007519631A/ja active Pending
- 2004-12-13 AU AU2004312311A patent/AU2004312311A1/en not_active Abandoned
- 2004-12-13 AT AT04812310T patent/ATE502009T1/de not_active IP Right Cessation
- 2004-12-21 AR ARP040104819A patent/AR047160A1/es unknown
- 2004-12-22 SV SV2004001984A patent/SV2005001984A/es not_active Application Discontinuation
-
2006
- 2006-05-31 IL IL176069A patent/IL176069A0/en unknown
- 2006-06-22 ZA ZA200605159A patent/ZA200605159B/en unknown
- 2006-07-21 NO NO20063381A patent/NO20063381L/no not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/840,417 patent/US7595339B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007519631A5 (enExample) | ||
| AR047160A1 (es) | Compuestos moduladores de cb1 | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister | |
| JP2007519754A5 (enExample) | ||
| RU2004113207A (ru) | Хинолиновые производные в качестве антагонистов нейропептида y | |
| NO20073366L (no) | 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose | |
| NO20161634A1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
| JP2010538076A5 (enExample) | ||
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| JP2008528467A5 (enExample) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| JP2007501831A5 (enExample) | ||
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| PE20040702A1 (es) | Heterociclos diarilicos sustituidos y procedimiento para su preparacion como medicamentos | |
| RU2012126987A (ru) | Спироиндолциклопропаниндолиноны в качестве модуляторов амрк | |
| TW200517109A (en) | Substituted pyridinones | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| MX2010005717A (es) | Derivados de isoxazolo-piridina. | |
| JP2011512412A5 (enExample) | ||
| ES2390459T3 (es) | Antagonistas de receptores de opioides | |
| JP2020534274A5 (enExample) | ||
| JP2009510086A5 (enExample) | ||
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |